Business Wire

ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million

Jaa

Regulatory News:

NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA OR JAPAN

ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initial closing of its previously announced global offering to specified categories of investors of an aggregate of 5,374,033 new ordinary shares, comprising an offer of 4,686,106 ordinary shares in the form of American Depositary Shares, each representing one ordinary share ("ADSs"), in the United States at an offering price of $23.26 per ADS and a concurrent private placement in Europe (including France) and other countries outside of the United States and Canada of 687,927 ordinary shares at an offering price of €20.00 per ordinary share. In addition, the underwriters for the global offering have exercised in full their option to purchase at the same price 702,915 additional ADSs and 103,189 additional ordinary shares in the global offering, with the additional closing expected to occur on November 16, 2017. Following the additional closing, aggregate net proceeds to ERYTECH, after deducting underwriting commissions and estimated offering expenses payable by ERYTECH, will be approximately $130 million. All of the securities sold in the global offering were offered by ERYTECH.

ERYTECH's ordinary shares are listed on Euronext Paris under the ticker symbol "ERYP". As of November 10, 2017, ERYTECH’s ADSs are listed on the Nasdaq Global Select Market under the ticker symbol "ERYP".

Jefferies LLC acted as global coordinator and joint book-runner for the global offering. Cowen and Company, LLC acted as joint book-runner and JMP Securities LLC acted as lead manager for the offering of ADSs in the United States. ODDO BHF SCA acted as joint book-runner for the private placement of ERYTECH’s ordinary shares in Europe.

In accordance with Article 6 of delegated regulation EU 2016/1052 of March 8, 2016, Jefferies LLC, acting as the stabilizing agent on its own behalf and on behalf of the other underwriters, reported that no stabilization activities had been carried out since November 10, 2017. The stabilization period is now closed.

The global offering was made only by means of a prospectus. A copy of the prospectus relating to the global offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About ERYTECH

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP). ERYTECH is also listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Disclaimer

This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to solicit the interest of the public in France, the United States, or in any other jurisdiction, in connection with any offer.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This announcement is not an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the "Prospectus Directive").

With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.

This document does not constitute an offer to the public in France and the securities referred to in this document can only be offered or sold in France pursuant to article L. 411-2-II of the French Monetary and Financial Code to (i) providers of third party portfolio management investment services, (ii) qualified investors (investisseurs qualifiés) acting for their own account and/or (iii) a limited group of investors (cercle restreint d’investisseurs) acting for their own account, all as defined in and in accordance with articles L. 411-1, L. 411-2 and D. 411-1 to D. 411-4 and D. 754-1 and D. 764-1 of the French Monetary and Financial Code.

This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This document does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or any other jurisdiction where such offer may be restricted. The securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or an applicable exemption from registration requirements under the Securities Act.

Contact information

ERYTECH
Naomi Eichenbaum
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
The Ruth Group
Lee Roth, +1 646 536 7012
Investor relations
lroth@theruthgroup.com
or
Kirsten Thomas
Media relations, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Porta Solutions Has Been Awarded as Excellence of the Year Innovation & Leadership for the Flexible Production at Le Fonti Awards 201721.11.2017 20:04Tiedote

Maurizio Porta, Porta Solutions’CEO triumphed at the 32th edition of the IAIR Awards. The Award Ceremony, held at the at London Stock Exchange on the 20th of October 2017, crowned him the Excellence of the Year, Innovation & Leadership, for the Flexible Production. For being an Italian excellence since 1958, innovative leader in the sector of productive flexibility in the manufacturing world. In particular to be able to aim continually and strategically on innovation and customization to ensure the best performance and highest quality. “Flexible Production: produce what you sell, no stock, no stress, more cash" says Maurizio Porta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005803/en/ Porta Solutions was awarded at the Le Fonti Awards (Photo: Business Wire) Today, the

China Global Investment Forum Hangzhou 2017 Opens21.11.2017 19:04Tiedote

On November 20, China Global Investment Forum Hangzhou 2017 opened. The forum was hosted by the Hangzhou Municipal People's Government and the Department of Commerce of Zhejiang Province, and organized by the Hangzhou Investment Promotion Bureau and Euromoney Institutional Investor PLC. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005723/en/ China Global Investment Forum Hangzhou 2017 Themed "Sharing the Opportunity of Hangzhou, Co-building a World-renowned City", the event brought together nearly 1,000 renowned experts, scholars and entrepreneurs from home and abroad, to interpret Hangzhou's economy, explore Hangzhou's future industries, look into the investment trends of the world and Hangzhou, and offer advice on improving Hangzhou's level of opening to the outside world, promoting

TechnipFMC, Saipem & Bureau Veritas Sign Partnership with Expert Teleportation21.11.2017 18:27Tiedote

BUREAU VERITAS, SAIPEM and TECHNIPFMC are teaming up to bring expert tele assistance to on-site operators within the specific context of the Oil & Gas sector (offshore, remote location, ATEX, IECEx, etc.) and have formed a collaborative partnership with EXPERT TELEPORTATION who will lead the project development. The 15-month long project will deliver a hands’ free device (modified smart glasses) adapted to use with personnel protective equipment. The adapted tool will connect an operator located on site anywhere in the world with a remote expert / analyst in real time via audio and video stream. This EXPERT TELEPORTATION project will enable higher operational efficiency, smarter and faster response time, improved safety and a reduced carbon footprint. ABOUT: In an increasingly competit

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) from EMA in Newly Diagnosed Multiple Myeloma21.11.2017 17:40Tiedote

Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), for the immunotherapy DARZALEX®▼ (daratumumab). The application seeks to broaden the existing marketing authorisation to include daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. “This submission to health authorities takes us one step closer to our goal of redefining combination therapy in multiple myeloma, with the potential to make daratumumab available to more patients throughout the treatment continuum: from newly diagnosed, to heavily pre-treated,” said Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen Europe, Middle East and Africa (EMEA). “We look forward to working closely with the

Andersen Global Announces Expansion in Uganda21.11.2017 17:30Tiedote

Andersen Global is proud to announce a presence in Uganda by way of a Collaboration Agreement with Ligomarc Advocates, a financial and corporate tax and legal firm. The firm is led by Managing Partner, Kabiito Karamagi. The addition of Ligomarc Advocates as a Collaborating Firm of Andersen Global continues the organization’s expansion in Africa. Ligomarc is Andersen Global’s fourth location in Africa. “Integrity, excellence, and putting the client at the center have always been of paramount importance to us, and our collaboration with Andersen Global will allow us to ensure our clients receive the best-in-class service internationally,” commented Kabiito Karamagi. “The team at Andersen shares our values of outstanding, seamless client service and independence—this is a natural fit.” Ligomarc Advocates was founded as a sole practice over fifteen years ago by Ruth Sebatindira,

Keio Plaza Hotel Tokyo Hosts "Sky Jazz Night" Events in the "Premier Grand" Club Lounge21.11.2017 17:00Tiedote

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host special jazz events for guests staying in our “Premier Grand” Club Floor on December 7, 8, 14, 15, and 16, 2017. A duo consisting of piano and contrabass artists will perform 30 minutes jazz sessions in our Club Lounge located on the 45th floor at 5:30p.m., 6:30p.m., and 7:30p.m. Guests listening to these jazz sessions can enjoy complimentary hors d’ oeuvres, and alcoholic and non-alcoholic beverages. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005017/en/ Club Floor "Premier Grand," Club Lounge (Photo: Business Wire) Our “Premier Grand” Club Floors were renovated and newly opened in December 2016, with guest rooms being fitted with various premium items

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme